Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial

Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert, Wally R. Smith, Hala Rimawi, Ersi Voskaridou, Birol Güvenç, Kenneth I. Ataga, Deborah Keefe, Kai Grosch, Jimmy Watson, Evgeniya Reshetnyak, Michele L. Nassin, Yvonne Dei‐Adomakoh